TNB-409
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 19, 2021
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
(GlobeNewswire)
- “Teneobio, Inc…announced today the publication of its bispecific human heavy chain only antibody (TNB-409) with selective IL-2βγ receptor heterodimeric agonist activity in Scientific Reports…By circumventing signaling through the α chain of the IL-2 receptor, TNB-409 minimizes Treg activation and retains robust immunostimulatory activity of T and NK cells in vitro and in vivo in monkey studies. TNB-409’s extended half-life and demonstrable safety in monkeys potentially confers a better therapeutic window for the treatment of solid tumors. TNB-409 is poised to enter phase 1 clinical studies in Q2 of 2022.”
New P1 trial • Preclinical • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1